We are live on ! Find out more
OIM

Oracle Investment Management Portfolio holdings

AUM $168M
1-Year Est. Return 42.86%
This Fund
S&P 500
This Quarter Est. Return
+6.78%
1 Year Est. Return
+42.86%
3 Year Est. Return
+864.89%
5 Year Est. Return
+1,153.35%
10 Year Est. Return
+22,228.86%
AUM
$198M
AUM Growth
+$14.5M
Cap. Flow
+$55.3M
Cap. Flow %
27.88%
Top 10 Hldgs %
93.89%
Holding
24
New
5
Increased
4
Reduced
4
Closed
7

Top Buys

Rank Stock Value
1
SWTX
SpringWorks Therapeutics
SWTX
+$12.7M
2
TDOC icon
Teladoc Health
TDOC
+$5.72M
3
ARDX icon
Ardelyx
ARDX
+$1.69M
4
RXRX icon
Recursion Pharmaceuticals
RXRX
+$875K
5
PLTR icon
Palantir
PLTR
+$87.8K

Top Sells

Rank Stock Value
1
BHVN icon
Biohaven
BHVN
+$6.55M
2
WGS icon
GeneDx Holdings
WGS
+$4.64M
3
BCRX icon
BioCryst Pharmaceuticals
BCRX
+$4.03M
4
PHAT icon
Phathom Pharmaceuticals
PHAT
+$1.18M
5
PACB icon
Pacific Biosciences
PACB
+$512K

Sector Composition

Rank Sector Weight
1 Healthcare 75.43%
2 Technology 1.26%
3 Consumer Discretionary 0.81%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
WGS icon
1
GeneDx Holdings
WGS
$1.84B
$85.9M 43.34%
969,954
-53,514
-5% -$4.64M
SWTX
2
DELISTED
SpringWorks Therapeutics
SWTX
$23.4M 11.83%
531,351
+276,578
+109% +$12.7M
XNTK icon
3
CALL
State Street SPDR NYSE Technology ETF
XNTK
$2B
$22.7M 11.46%
+280,000
New +$58.3M
BHVN icon
4
Biohaven
BHVN
$2.07B
$16M 8.08%
665,945
-185,825
-22% -$6.55M
ARDX icon
5
Ardelyx
ARDX
$1.25B
$11.8M 5.96%
2,404,438
+315,007
+15% +$1.69M
VKTX icon
6
CALL
Viking Therapeutics
VKTX
$3.93B
$8.13M 4.1%
+336,700
New +$10.6M
ARDX icon
7
CALL
Ardelyx
ARDX
$1.25B
$5.57M 2.81%
1,133,500
+548,800
+94% +$2.95M
TDOC icon
8
Teladoc Health
TDOC
$1.69B
$4.5M 2.27%
+565,900
New +$5.72M
QDEL icon
9
QuidelOrtho
QDEL
$1.14B
$4.14M 2.09%
118,291
– –
BHVN icon
10
CALL
Biohaven
BHVN
$2.07B
$3.89M 1.96%
161,900
-38,100
-19% -$1.34M
PTON icon
11
CALL
Peloton Interactive
PTON
$2.84B
$3.16M 1.59%
+500,000
New +$3.93M
FORA
12
DELISTED
Forian
FORA
$2.73M 1.38%
1,366,107
– –
PLTR icon
13
Palantir
PLTR
$296B
$2.49M 1.26%
29,500
+1,000
+4% +$87.8K
CAVA icon
14
CAVA Group
CAVA
$7.57B
$1.61M 0.81%
18,600
– –
TDOC icon
15
CALL
Teladoc Health
TDOC
$1.69B
$1.15M 0.58%
144,300
-153,400
-52% -$1.55M
RXRX icon
16
Recursion Pharmaceuticals
RXRX
$1.62B
$635K 0.32%
+120,000
New +$875K
BIIB icon
17
Biogen
BIIB
$30.4B
$330K 0.17%
2,412
– –
BCRX icon
18
BioCryst Pharmaceuticals
BCRX
$2.48B
– –
-535,558
Closed -$4.03M
EYPT icon
19
EyePoint Inc
EYPT
$1B
– –
-32,500
Closed -$242K
NVAX icon
20
CALL
Novavax
NVAX
$1.21B
– –
-466,000
Closed -$3.75M
PACB icon
21
Pacific Biosciences
PACB
$432M
– –
-279,638
Closed -$512K
PHAT icon
22
Phathom Pharmaceuticals
PHAT
$930M
– –
-145,064
Closed -$1.18M
SWTX
23
CALL
DELISTED
SpringWorks Therapeutics
SWTX
– –
-55,800
Closed -$2.02M
XLV icon
24
PUT
State Street Health Care Select Sector SPDR ETF
XLV
$43.2B
– –
-115,000
Closed -$15.8M

Similar funds

BIO
Blue Investment Opportunities Miami Beach, Florida $168M AUM 21.32% 1-Year Est. Return
OBWA
Oak Barrel Wealth Advisory Reston, Virginia $167M AUM
EECFX
EnCap Energy Capital Fund XII Houston, Texas $169M AUM
PW
Pandora Wealth Oakbrook Terrace, Illinois $165M AUM 18.5% 1-Year Est. Return
PWA
Principia Wealth Advisory Dallas, Texas $160M AUM 37.01% 1-Year Est. Return
AIMU
Allianz Investment Management US Minneapolis, Minnesota $160M AUM 4.75% 1-Year Est. Return
HIA
Harvest Investment Advisors Tallahassee, Florida $176M AUM
ACA
AG Campbell Advisory Baltimore, Maryland $158M AUM

Oracle Investment Management's Q1 2025 Portfolio in Review

As of Q1 2025, Oracle Investment Management held 24 positions worth $198M, up 7.9% from $184M the previous quarter. Its ten largest holdings account for 94% of the portfolio.

Oracle Investment Management deployed $55.3M of net new capital in Q1 2025, opening 5 new positions and adding to 4 existing holdings. Its largest new stake was Teladoc Health: 565,900 shares worth $4.5M.

By sector, the portfolio is most concentrated in Healthcare at 75% of assets, down from 79% a quarter earlier, followed by Technology and Consumer Discretionary.

On the sell side, the largest reduction was Biohaven, an estimated $6.55M trimmed.

  • Oracle Investment Management's largest Q1 2025 buy was Teladoc Health: 565,900 shares worth $4.5M.
  • Oracle Investment Management added most to SpringWorks Therapeutics in Q1 2025, an estimated $12.7M increase.
  • Oracle Investment Management's biggest Q1 2025 reduction was Biohaven, cutting an estimated $6.55M.
  • Oracle Investment Management fully exited BioCryst Pharmaceuticals in Q1 2025, selling an estimated $4.03M.
  • Oracle Investment Management's ten largest holdings make up 94% of its $198M portfolio in Q1 2025.
  • Oracle Investment Management opened 5 new positions and closed 7 in Q1 2025.
  • Oracle Investment Management's portfolio value rose 7.9% quarter-over-quarter to $198M.

Based on Oracle Investment Management's 13F filing for Q1 2025, filed 15 May 2025.